Morgan Stanley resumed coverage on Incyte with a new price target
Stocks in this Quantisnow insightHealth Care
Historical context for INCY
Across the 27 sessions after earlier INCY headlines, the stock closed higher 10 times and lower 17 times, with a median move of 1.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | INCY | SPY |
|---|---|---|---|
| Oct 19, 2026 | Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 | +0.2% | +0.4% |
| Oct 8, 2026 | Incyte to Report Third Quarter Financial Results | -0.6% | -0.4% |
| Oct 6, 2026 | Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil | -1.2% | +0.5% |
| Sep 22, 2026 | Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio | +1.8% | -0.0% |
| Sep 21, 2026 | Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia | -0.5% | +1.6% |
| Sep 1, 2026 | Incyte to Present at Upcoming Investor Conferences | +1.5% | -0.7% |
Quantisnow market dataNASDAQ
INCY
Incyte Corp.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
Get push alerts for INCY
Full INCY profile on Quantisnow Follow INCY and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time